KINTARA THERAPEUTICS KTRA 深 沪
已收盘 10-17 16:00:00 美东时间
0.2154
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.2154
- 总市值 1198.93万
- 52周最高 156.80
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.835
- 委 比 0.00%
- 总股本 5566.06万
- 历史最高 190225.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.835
- 每 手 1
- 风险率 22.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses
Kymera Therapeutics announced positive Phase 1 results for KT-621, an oral STAT6 degrader, showing rapid STAT6 degradation in blood and skin, Th2 biomarker reductions, and a safety profile similar to placebo. KT-621’s data highlight its potential to mimic dupilumab-like activity while offering once-daily oral convenience. The company plans to report Phase 1b AD trial results and initiate Phase 2b studies in AD and asthma in 4Q25 and 1Q26, respect...
09-17 11:00
Kymera Therapeutics Announces Proposed Public Offering
Kymera Therapeutics announced a $250 million underwritten public offering of its common stock, with an option for underwriters to purchase up to an additional $37.5 million. Proceeds will be used to advance its pipeline of degrader programs for immunological diseases and general corporate purposes. Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen and Leerink Partners are joint book-running managers. The offering is subject to market conditions an...
06-25 20:05
Kintara stock climbs 10% on TuHURA merger update
Shares of Kintara Therapeutics (NASDAQ:KTRA) climbed 10% Monday after the company announced the record date for contingent value rights, or CVRs, to be issued under its merger agreement with TuHURA Bi...
2024-10-15 01:48
Kintara Therapeutics Reveals Improved Financials, Merger Plans
The latest update is out from Kintara Therapeutics ( ($KTRA) ). Kintara Therape...
2024-10-08 19:28
Kintara Therapeutics 2024 EPS $(0.32) Up From $(9.27) YoY; Cash And Cash Equivalents $4.9M
Recent Corporate Developments As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"),
2024-10-08 19:16
Kintara Postpones Stockholder Meeting for Merger Decision
Kintara Therapeutics (KTRA) has released an update. Kintara Therapeutics has po...
2024-09-20 21:37
Kintara Therapeutics: Clinical Trial Resumes Amid Merger Uncertainties
Kintara Therapeutics (KTRA) has provided an update. Kintara Therapeutics and Tu...
2024-08-19 21:27
Kintara Therapeutics Eyes Acquisition Amidst Cautionary Advice
Kintara Therapeutics (KTRA) has shared an update. Kintara Therapeutics and TuHU...
2024-07-08 18:57
Kintara Therapeutics Outlines Progress and Potential Risks
An announcement from Kintara Therapeutics (KTRA) is now available. Kintara Ther...
2024-07-01 21:02
Kintara’s Novel Vaccine Shows Promise in Cancer Trial
Kintara Therapeutics (KTRA) has released an update. Kintara Therapeutics, in co...
2024-06-03 21:13
